ZymoGenetics -- Post-Op help
ZymoGenetics (ZGEN) was added to the Barchart Van Meerten Speculative portfolio this morning. They are an independent biopharmaceutical company focused on the discovery, development and commercialization of therapeutic proteins for the prevention or treatment of human diseases. They have also developed drugs and proteins that are used both during surgery and in post-op recovery to control bleeding and infection.
Wall Street brokerages have 6 buy and 3 hold recommendations based on projected increases of 15.80% in sales and 71.00% in earnings this year.
The general investing public as measured on Motley Fool thinks the stock will beat the market by a vote of 146 to 28 with the All Stars also voting 48 to 11.
I look for this to be a short term technical play. The price has appreciated 31.77% this month on 15 new highs in 20 sessions including 4 of the last 5. Barchart has 11 of 13 technical indicators positive giving an 80% buy signal. The 14 day Relative Strength index is 71.67% and rising. The stock recently traded at 5.41 will above its 50 day moving average of 4.43.
Jim Van Meerten is an investor who writes on investing here and on Barchart Portfolio Blogs. Please leave a comment below or email JimVanMeerten@gmail.com.
Disclosure: No positions in the stock mentioned at the time of publication